🔎 Trials Near Me

Gara Jalqabaatti › Kansarii Ovarii › Oklahoma

Qorannoo klinikaalii Kansarii Ovarii Oklahoma keessatti

Qorannoo 31 Kansarii Ovarii f Oklahoma keessatti hirmaatuu jiru.

Magaalota Oklahoma keessatti

Takkalaa qorannoo (Ingiliffa)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 45 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06995898

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • OU Health, Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT05739981

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Oklahoma, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 01-Onk-2026 · NCT07024784

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05867251

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dubartoota · Haaromfame 25-Ful-2026 · NCT03564340

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213804

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • University of Oklahoma, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06128551

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT07318558

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • OU Health Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06303505

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT06824467

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 26-Hag-2026 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • OU Health Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 15 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06276491

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Namoota walitti qabaa jira
Umuriin 35 hanga 50 · Dubartoota · Haaromfame 07-Hag-2026 · NCT04251052

A Study of DM002 in Patients With Advanced Solid Tumors

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06751329

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • University of Oklahoma - Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

Clinical Pre-screening Protocol for Ovarian Cancer

  • OU Health Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Dubartoota · Haaromfame 30-Ado-2026 · NCT03877796

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Oklahoma Cancer Specialists and Research Institute, Tulsa
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ado-2026 · NCT06161025

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • University of Oklahoma, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 14-Ado-2026 · NCT04606914

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • OU Health University of Oklahoma Medical Center, Oklahoma City
  • Stephenson Cancer Center (chemo location), Oklahoma City
  • University of Oklahoma Health Science Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT04389632

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT05377996

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

  • University of Oklahoma Health Sciences Center, Oklahoma City
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 50 hanga 74 · Dubartoota · Haaromfame 06-Cam-2026 · NCT00539162

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

  • Stephenson Cancer Center, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ama-2026 · NCT06234423

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ama-2026 · NCT06999187

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 23-Mud-2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Tulsa
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

  • Exelixis Clinical Site #13, Oklahoma City
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Ful-2025 · NCT05932862

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.